| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000020640 |
| Receipt No. | R000023821 |
| Official scientific title of the study | Investigation of the etiology of central serous chorioretinopathy using en face OCT and indocyanine green angiography |
| Date of disclosure of the study information | 2016/02/10 |
| Last modified on | 2019/03/05 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Investigation of the etiology of central serous chorioretinopathy using en face OCT and indocyanine green angiography | |
| Title of the study (Brief title) | Possible Etiologies of Central Serous Chorioretinopathy | |
| Region |
|
|
| Condition | ||
| Condition | Central Serous Chorioretinopathy | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To clarify the etiology of central serous chorioretinopathy using indocyanine green angiography and en face-OCT imaging. |
| Basic objectives2 | Others |
| Basic objectives -Others | To clarify the etiology of eye disease |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | To compare the abnormal areas in central serous chorioretinopathy using en face-OCT and indocyanine green angiography. |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with central serous chorioretinopathy. | |||
| Key exclusion criteria | Patients with polypoidal choroidal vasculopathy and age-related macular diseases, based on fluorescein angiography, indocyanine green angiography and OCT findings, were excluded. | |||
| Target sample size | 25 | |||
| Research contact person | |
| Name of lead principal investigator | Ari Shinojima |
| Organization | Nihon University School of Medicine |
| Division name | Division of Ophthalmology, Department of Visual Science |
| Address | 1-6, Surugadai, Kanda, Chiyoda-ku, Tokyo |
| TEL | 03-3293-1711 |
| shinojima.ari@nihon-u.ac.jp | |
| Public contact | |
| Name of contact person | Ari Shinojima |
| Organization | Nihon University School of Medicine |
| Division name | Division of Ophthalmology, Department of Visual Science |
| Address | 1-6, Surugadai, Kanda, Chiyoda-ku, Tokyo |
| TEL | 03-3293-1711 |
| Homepage URL | |
| shinojima.ari@nihon-u.ac.jp | |
| Sponsor | |
| Institute | Nihon University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Novartis Pharma (to A.S.) |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | https://www.ncbi.nlm.nih.gov/pubmed/27532435 |
| Publication of results | Published |
| URL releasing results | https://www.ncbi.nlm.nih.gov/pubmed/27532435 |
| Results | All 25 CSC eyes and 13 contralateral eyes showed abnormal hypofluorescent areas on late-phase ICGA and hyperreflective areas on en-face OCT from BrM to the choriocapillaris, and these findings correlated with the abnormal areas (r = 0.9988; p < 0.001). |
| Other related information | Study design (Observational case series study).
We retrospectively studied all eyes of consecutive untreated patients at our Hospital, between April 2015 and December 2015. Items investigated (We investigated the area of the abnormal portion on en face images and the area of the abnormal portion in angiography images.) |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023821 |